Active Solicitation · DEPARTMENT OF HEALTH AND HUMAN SERVICES
AI Summary
The National Institutes of Health is seeking to acquire the Ella Immunoassay System for high-throughput, high-sensitivity analysis of biomarkers in neuroimmunology research. This automated machine is crucial for quantifying indicators of neuroinflammatory diseases, supporting ongoing investigations in the field. Bidders should be prepared to provide a solution that meets the specified analytical precision and sample volume requirements.
The Translational Neuroradiology Section (TNS) of the National Institute of Neurological Disorders and Stroke (NINDS) is focused on elucidating the mechanisms by which multiple sclerosis (MS) and related neuroinflammatory pathologies impact the central nervous system (CNS). Given the multifactorial nature of these diseases, high-throughput, high-sensitivity technologies are essential for comprehensive immune profiling and biomarker quantification. The Ella Immunoassay System (Bio-Techne) offers an unparalleled solution for multiplexed, protein-based analysis of serum and plasma samples, with minimal sample volume requirements and superior analytical precision.
Specifically, the Ella enables reproducible quantification of biomarkers such as neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), which are critical indicators of axonal damage and astrocyte activation, respectively. Collaborating researchers have consistently cited Ella’s rapid turnaround, high sensitivity, and platform stability as key factors supporting its use in translational neuroimmunology studies. Acquisition or continued access to this system is essential to support our ongoing investigations and to maintain the rigor and reproducibility necessary for high-impact CNS researc
ELLA INSTRUMENT- AUTOMATED IMMUNOASSAY MACHINE ACQUISITION is a federal acquisition solicitation issued by DEPARTMENT OF HEALTH AND HUMAN SERVICES. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.
SamSearch Platform
AI-powered intelligence for the right opportunities, the right leads, and the right time.